

To: [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]
 [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]
 [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]
From: [redacted]
Sent: Tue 3/23/2021 11:08:26 AM
Subject: IMI2 PROMISE Consortium Agreement final version
Received: Tue 3/23/2021 11:08:28 AM
[15MARCH21 -- V3 -- PROMISE Consortium Agreement \(version to be taken into account\).docx](#)

Ha allen,

Zie bijgevoegd de consortium agreement van PROMISE, waarvoor we uiterlijk vrijdag een general approval moeten geven.

Juridisch Advies van RIVM is akkoord.

Het enig waar ik nog mee zit is de 'background' (zie pagina 112). Het is mij, ondanks navraag op meerdere plekken, nog steeds niet helemaal duidelijk wat nu de voor- en nadelen zijn van het opvoeren van een background; bescherm je iets of leg je je juist extra vast? Ik heb nu ongeveer hetzelfde opgevoerd als bij RESCEU, dus hopelijk is het goed zo, maar lang niet alle partijen hebben een background opgevoerd, dus het nut en belang zie ik niet helemaal. Ik heb deze vraag nu nogmaals aan team-it [redacted] gevraagd, hopelijk krijg ik nog op tijd antwoord van ze. Of is hier iemand van jullie die hier ervaring mee heeft?

Bij geen tegenbericht zal ik donderdag de CA goedkeuren.

Dank en groeten [redacted]

From: [redacted]@sanofi.com
Sent: vrijdag 19 maart 2021 17:35
To: [redacted]@astrazeneca.com; [redacted] [JRDBE] <[redacted]@its.jnj.com>; [redacted] [redacted] [redacted]
 <[redacted]@ssi.dk>; [redacted] [redacted] <[redacted]@paediatrics.ox.ac.uk>; [redacted] <[redacted]@gsk.com>; [redacted] [redacted]
 <[redacted]@rivm.nl>; [redacted] <[redacted]@teamitresearch.com>; [redacted] [redacted] <[redacted]@Novavax.com> [redacted]
 [redacted] <[redacted]@sergas.es>; [redacted] <[redacted]@umcutrecht.nl>; [redacted] [redacted]
 <[redacted]@ITS.JNJ.com>; [redacted] <[redacted]@pentafoundation.org>; [redacted] <[redacted]@pfizer.com>;
 [redacted] [redacted] <[redacted]@teamitresearch.com>; [redacted] [redacted] [redacted] <[redacted]@sergas.es>; [redacted]
 <[redacted]@opbg.net>; [redacted] <[redacted]@pfizer.com>; [redacted] [redacted] <[redacted]@thl.fi>;
 [redacted] [redacted] @tyks.fi>; [redacted] [redacted] <[redacted]@verwaltung.uni-halle.de>; [redacted]
 <[redacted]@astrazeneca.com>; [redacted] <[redacted]@Novavax.com>; [redacted] [redacted] <[redacted]@gsk.com>; [redacted]
 [redacted] [redacted] @nivel.nl>; [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@sergas.es>; [redacted]
 [redacted] <[redacted]@gsk.com>; [redacted] <[redacted]@umcutrecht.nl>; [redacted] [redacted]
 <[redacted]@juliusclinical.com>; [redacted] <[redacted]@imperial.ac.uk>; [redacted] [redacted] <[redacted]@nivel.nl>;
 [redacted] [redacted] <[redacted]@teamitresearch.com>; [redacted] <[redacted]@pfizer.com>; [redacted]
 [redacted] @astrazeneca.com; [redacted] <[redacted]@paediatrics.ox.ac.uk>; [redacted] [redacted] <[redacted]@ssi.dk>;
 [redacted] [redacted] <[redacted]@gsk.com>; [redacted] <[redacted]@gsk.com>; [redacted] [redacted]
 <[redacted]@teamitresearch.com>; [redacted] <[redacted]@sergas.es>; [redacted] [redacted]
 <[redacted]@uantwerpen.be>; [redacted] <[redacted]@gsk.com>; [redacted] [redacted] @uk-halle.de; [redacted]
 [redacted] <[redacted]@nivel.nl>; [redacted] [redacted] @tyks.fi>; [redacted] [redacted] Anne <[redacted]@pfizer.com>; [redacted]
 [redacted] <[redacted]@utu.fi>; [redacted] [redacted] @regionh.dk; [redacted] <[redacted]@imperial.ac.uk>; [redacted] [redacted] [redacted]
 <[redacted]@pfizer.com>; [redacted] <[redacted]@ed.ac.uk>; [redacted] <[redacted]@gva.es>;
 [redacted] [redacted] @ITS.JNJ.com>; [redacted] [redacted] @invigolaw.be>
Cc: [redacted] <[redacted]@sanofi.com>; [redacted] [redacted] /FR <[redacted]@sanofi.com>; [redacted] [redacted] /DE
 <[redacted]@sanofi.com>

Subject: CANCEL AND REPLACE - IMI2 PROMISE Consortium Agreement final version

Dear Partners,

Thanks for taking into consideration the proposal here attached following last update.

Best,

Dear all,

We received feedbacks from all partners and therefore I circulate a final version of the document. Some additional appendices (14 and 15) have been provided by GSK and contain the commonly accepted good practices in IMI practices for Clinical Trial and Data integrity.

We assume then that this version should be acceptable for all partners as there is no more deadlock.

- To fit with IMI deadline, we now need a general approval from each partner on the main terms of the Consortium Agreement by March 26th to be then submitted to IMI.

Thanks for revising any information related to your entity identification if not already done.

We will then initiate the signature process if we are all aligned. Thanks a lot.

Have a nice week end,

Kind Regards,

5.1.2e

Vaccines GBU

TÉL. : 5.1.2e

Campus Carteret (C1-1) – 14 Espace Henry Vallée - 69007 Lyon – France

SANOVI PASTEUR 